Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of Success Rates Between Laser Photocoagulation and Intravitreal Anti-Vascular Endothelial Growth Factor Injection for the Treatment of Retinopathy of Prematurity in a Tertiary Referral Center: An 11-Year Survey.

Journal of clinical practice and research·2026
Same author

Comparison between Ahmed glaucoma valve implant and Keiki Mehta body pressure glaucoma implant in neovascular glaucoma: 24-month results.

International journal of ophthalmology·2026
Same author

Endoscopic dacryocystorhinostomy in the pediatric population: a systematic review and meta-analysis.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie·2026
Same author

Age- and Sex-Related Normative Anterior Segment Parameters Using Swept-Source OCT: Insights from Pediatric to Elderly Populations.

Journal of clinical medicine·2025
Same author

Agreement of Corneal Measurements With Swept-Source Optical Coherence Tomography (Anterion) and Scheimpflug (Sirius) Device in Eyes With Dermatochalasis.

Cureus·2025
Same author

Clinical Features, Complications, and Treatment Outcomes of Pediatric Pars Planitis Cases in a Tertiary Referral Center.

Ocular immunology and inflammation·2025

Related Experiment Video

Updated: May 29, 2026

Corneal Sensitivity Testing Procedure for Ophthalmologic and Optometric Patients
04:00

Corneal Sensitivity Testing Procedure for Ophthalmologic and Optometric Patients

Published on: August 2, 2024

Ocular Behçet disease: current therapeutic approaches.

Cem Evereklioglu1

  • 1Division of Uvea-Behçet Unit, Department of Ophthalmology, Erciyes University Medical Faculty, Kayseri, Turkey. evereklioglu@erciyes.edu.tr

Current Opinion in Ophthalmology
|September 8, 2011
PubMed
Summary

Ocular Behçet disease (OBD) requires prompt recognition and treatment. Advanced therapies like biologics show promise for managing severe ocular inflammation and preventing vision loss.

More Related Videos

Intracameral Injection in Rats with Low Risk of Adverse Effects
06:19

Intracameral Injection in Rats with Low Risk of Adverse Effects

Published on: May 31, 2024

Related Experiment Videos

Last Updated: May 29, 2026

Corneal Sensitivity Testing Procedure for Ophthalmologic and Optometric Patients
04:00

Corneal Sensitivity Testing Procedure for Ophthalmologic and Optometric Patients

Published on: August 2, 2024

Intracameral Injection in Rats with Low Risk of Adverse Effects
06:19

Intracameral Injection in Rats with Low Risk of Adverse Effects

Published on: May 31, 2024

Area of Science:

  • Ophthalmology
  • Rheumatology
  • Immunology

Background:

  • Ocular Behçet disease (OBD) is a severe inflammatory condition affecting the eye.
  • It predominantly impacts young adults, potentially leading to significant vision impairment.

Purpose of the Study:

  • To highlight the importance of early diagnosis and current treatment strategies for recurrent hypopyon iridocyclitis and panuveitis in OBD.
  • To inform physicians about the evolving therapeutic landscape for ocular inflammation in Behçet disease.

Main Methods:

  • Review of current literature on the treatment of ocular inflammation in Behçet disease.
  • Focus on emerging biologic therapies and their efficacy.

Main Results:

  • Biologic agents, including interferon-α, rituximab, and TNF inhibitors (infliximab, adalimumab), are increasingly used.
  • These treatments are effective for severe sight-threatening conditions like retinal vasculitis and cystoid macular edema (CME).

Conclusions:

  • Biological agents hold significant potential for managing OBD.
  • Early ophthalmologic consultation is crucial for patients with systemic Behçet disease to prevent sight-threatening complications.
  • Infliximab is effective for acute panuveitis, with repeated infusions beneficial for refractory uveoretinitis and CME remission.